Contrasting LakeShore Biopharma (NASDAQ:LSB) and MiNK Therapeutics (NASDAQ:INKT)

MiNK Therapeutics (NASDAQ:INKT) and LakeShore Biopharma (NASDAQ:LSB) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, institutional ownership, earnings, valuation and profitability.

Earnings and Valuation

This table compares MiNK Therapeutics and LakeShore Biopharma”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiNK Therapeutics	N/A	N/A	-$9.51 million	($2.88)	-5.22
LakeShore Biopharma	$85.67 million	0.13	-$13.93 million	N/A	N/A

MiNK Therapeutics has higher earnings, but lower revenue than LakeShore Biopharma.

Profitability

This table compares MiNK Therapeutics and LakeShore Biopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MiNK Therapeutics	N/A	N/A	-227.24%
LakeShore Biopharma	N/A	N/A	N/A

Institutional and Insider Ownership

2.9% of MiNK Therapeutics shares are held by institutional investors. Comparatively, 52.6% of LakeShore Biopharma shares are held by institutional investors. 22.5% of MiNK Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Volatility and Risk

MiNK Therapeutics has a beta of 0.33, meaning that its stock price is 67% less volatile than the S&P 500. Comparatively, LakeShore Biopharma has a beta of 0.56, meaning that its stock price is 44% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations for MiNK Therapeutics and LakeShore Biopharma, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiNK Therapeutics	2	1	2	1	2.33
LakeShore Biopharma	0	0	0	0	0.00

MiNK Therapeutics currently has a consensus target price of $37.50, suggesting a potential upside of 149.67%. Given MiNK Therapeutics’ stronger consensus rating and higher probable upside, equities analysts plainly believe MiNK Therapeutics is more favorable than LakeShore Biopharma.

Summary

MiNK Therapeutics beats LakeShore Biopharma on 6 of the 10 factors compared between the two stocks.

About MiNK Therapeutics

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.

About LakeShore Biopharma

LakeShore Biopharma Co., Ltd. engages in the provision of discovering, developing, manufacturing, and commercializing vaccines and therapeutic biologics for infectious diseases and cancer. It focuses on developing PIKA technology platform. It operates through the People’s Republic of China and Other Countries or Regions. The company was founded by Yi Zhang on November 16, 2020 and is headquartered in Beijing, China.